Last reviewed · How we verify
QLC7401
QLC7401 is a small-molecule inhibitor that targets specific cellular pathways involved in disease progression.
At a glance
| Generic name | QLC7401 |
|---|---|
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
QLC7401 is an investigational compound in Phase 3 development by Qilu Pharmaceutical. Limited public information is available regarding its precise molecular mechanism and target. The drug is being evaluated for potential therapeutic benefit in its indicated disease area.
Approved indications
Common side effects
Key clinical trials
- QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) (PHASE3)
- QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C) (PHASE3)
- QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia (PHASE3)
- Pharmacokinetics and Pharmacodynamics Study (PHASE1)
- Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |